⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25349215 | 0.72 | — | — | |
| SCHEMBL17837252 | 0.72 | USP30 (0.30) | — | |
| SCHEMBL17837259 | 0.67 | USP30 (0.40) | — | |
| SCHEMBL25349493 | 0.67 | BACE1 (0.32) | — | |
| SCHEMBL1829293 | 0.63 | LPL (0.35) | — | |
| SCHEMBL25234421 | 0.63 | CDC7 (0.44) | — | |
| SCHEMBL24525757 | 0.62 | CES1 (0.32) | — | |
| SCHEMBL20749433 | 0.62 | AKR1B1 (0.42) | — | |
| SCHEMBL25222583 | 0.61 | CDC7 (0.36) | — | |
| SCHEMBL31514422 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163074-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2025-05-22 | — | — | US | disclosed |
| US-12129262-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-10-29 | — | — | US | disclosed |
| US-20220267345-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2022-08-25 | — | — | US | disclosed |
| WO-2022133215-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-06-23 | — | — | WO | disclosed |